JP7008014B2 - 有効な部位特異的バイオコンジュゲーションのためのトランスグルタミンタグ - Google Patents

有効な部位特異的バイオコンジュゲーションのためのトランスグルタミンタグ Download PDF

Info

Publication number
JP7008014B2
JP7008014B2 JP2018506297A JP2018506297A JP7008014B2 JP 7008014 B2 JP7008014 B2 JP 7008014B2 JP 2018506297 A JP2018506297 A JP 2018506297A JP 2018506297 A JP2018506297 A JP 2018506297A JP 7008014 B2 JP7008014 B2 JP 7008014B2
Authority
JP
Japan
Prior art keywords
seq
tyfqayg
amino acid
antibody
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018506297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529321A (ja
JP2018529321A5 (enExample
Inventor
ビルギット ピアター
ウルリヒ ベッツ
ハーラルト コルマー
ヴァネサ ジークムント
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2018529321A publication Critical patent/JP2018529321A/ja
Publication of JP2018529321A5 publication Critical patent/JP2018529321A5/ja
Application granted granted Critical
Publication of JP7008014B2 publication Critical patent/JP7008014B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018506297A 2015-08-07 2016-08-04 有効な部位特異的バイオコンジュゲーションのためのトランスグルタミンタグ Expired - Fee Related JP7008014B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15180278 2015-08-07
EP15180278.2 2015-08-07
PCT/EP2016/001344 WO2017025179A1 (en) 2015-08-07 2016-08-04 A transglutamine tag for efficient site-specific bioconjugation

Publications (3)

Publication Number Publication Date
JP2018529321A JP2018529321A (ja) 2018-10-11
JP2018529321A5 JP2018529321A5 (enExample) 2019-09-12
JP7008014B2 true JP7008014B2 (ja) 2022-02-10

Family

ID=53785570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506297A Expired - Fee Related JP7008014B2 (ja) 2015-08-07 2016-08-04 有効な部位特異的バイオコンジュゲーションのためのトランスグルタミンタグ

Country Status (9)

Country Link
US (1) US11130818B2 (enExample)
EP (1) EP3331904B1 (enExample)
JP (1) JP7008014B2 (enExample)
CN (1) CN107922479A (enExample)
AU (1) AU2016306907A1 (enExample)
CA (1) CA2994741A1 (enExample)
ES (1) ES2855998T3 (enExample)
IL (1) IL256810B (enExample)
WO (1) WO2017025179A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3419670A2 (en) * 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
EP3272864A1 (en) * 2016-07-20 2018-01-24 Paul Scherrer Institut Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
AU2018337671B2 (en) 2017-09-19 2021-03-04 Paul Scherrer Institut Transglutaminase conjugation method and linker
DK3886914T3 (da) * 2018-11-30 2023-07-03 Bristol Myers Squibb Co Antistof omfattende en glutaminholdig letkæde-c-terminal forlængelse, konjugater deraf og fremgangsmåder samt anvendelser
CN113613679A (zh) 2019-03-19 2021-11-05 保罗·谢勒学院 基于甘氨酸的接头的转谷氨酰胺酶缀合方法
PT3865155T (pt) * 2020-02-13 2023-01-02 Orano Med Processo para modificação específica de local de um anticorpo
EP4213886A1 (en) 2020-09-18 2023-07-26 Araris Biotech AG Transglutaminase conjugation method with amino acid-based linkers
JP7789396B2 (ja) 2020-10-25 2025-12-22 アラリス バイオテック アーゲー 抗体－リンカーコンジュゲートを生成するための手段および方法
EP4422695A1 (en) 2021-10-25 2024-09-04 Araris Biotech AG Methods for producing antibody-linker conjugates
WO2023156849A2 (en) * 2022-02-17 2023-08-24 Revolo Biotherapeutics Limited Method of producing peptide derived from chaperonin 60.1
KR20240150807A (ko) 2022-02-22 2024-10-16 아라리스 바이오테크 아게 2개 이상의 페이로드를 포함하는 펩티드 링커
US20240337664A1 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
WO2025026338A1 (zh) * 2023-07-31 2025-02-06 石药集团巨石生物制药有限公司 具有高药物负载的抗体-药物缀合物及其用途
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
WO2026013234A1 (en) 2024-07-10 2026-01-15 Araris Biotech Ag Triple-payload antibody-drug conjugates (adcs)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015097267A1 (en) 2013-12-23 2015-07-02 Covalab mTG SUBSTRATES FOR COVALENT CONJUGATION OF COMPOUNDS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
WO2004108667A2 (en) * 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
EP2033662B1 (en) * 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
EP4032902A1 (en) * 2015-12-18 2022-07-27 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015097267A1 (en) 2013-12-23 2015-07-02 Covalab mTG SUBSTRATES FOR COVALENT CONJUGATION OF COMPOUNDS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOMOLECULES，2013年，Vol. 3, No. 4，pp. 870-888
Biosci. Biotechnol. Biochem.，2009年，Vol. 73, No. 5，pp. 993-999
日本農芸化学会大会講演要旨集 ２００８年度（平成２０年度）大会，2008年03月05日，シ66, 4SY18-1

Also Published As

Publication number Publication date
IL256810B (en) 2021-10-31
EP3331904B1 (en) 2020-12-23
ES2855998T3 (es) 2021-09-27
US20190194344A1 (en) 2019-06-27
CA2994741A1 (en) 2017-02-16
JP2018529321A (ja) 2018-10-11
EP3331904A1 (en) 2018-06-13
WO2017025179A1 (en) 2017-02-16
WO2017025179A8 (en) 2018-04-19
AU2016306907A1 (en) 2018-03-29
AU2016306907A9 (en) 2019-07-25
US11130818B2 (en) 2021-09-28
CN107922479A (zh) 2018-04-17
IL256810A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
EP3331904B1 (en) A transglutamine tag for efficient site-specific bioconjugation
JP7360377B2 (ja) アントラサイクリン誘導体を含む、結合タンパク質薬物複合体（Ｂｉｎｄｉｎｇ ｐｒｏｔｅｉｎ ｄｒｕｇ ｃｏｎｊｕｇａｔｅｓ）
JP6860601B2 (ja) 改変した抗体組成物、それを作製および使用する方法
RU2747581C2 (ru) Конъюгированные иммуноглобулины с c-концевым лизином
US10864278B2 (en) Antibody-drug conjugates and immunotoxins
Hong et al. Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies
JP7041077B2 (ja) リジン結合体化免疫グロブリン
JP6616776B2 (ja) 抗体−薬物複合体及び免疫毒素
US11235063B2 (en) Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
JP2020530554A (ja) 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
US11723984B2 (en) Method for conjugating antibody and physiologically active substance
US20220008551A1 (en) Polypeptide conjugates
TW202535941A (zh) 具有特製藥物對抗體比之抗體-藥物結合物
WO2025121429A1 (ja) Ｆｃ－細胞複合体およびその製造方法
EA040604B1 (ru) Конъюгаты, связывающие белок-лекарственное средство, содержащие производные антрациклина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220107

R150 Certificate of patent or registration of utility model

Ref document number: 7008014

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees